EP2794007A4 - Compositions et procédés pour le traitement de thrombose et la prolongation de la survie de plaquettes stockées - Google Patents

Compositions et procédés pour le traitement de thrombose et la prolongation de la survie de plaquettes stockées

Info

Publication number
EP2794007A4
EP2794007A4 EP12859158.3A EP12859158A EP2794007A4 EP 2794007 A4 EP2794007 A4 EP 2794007A4 EP 12859158 A EP12859158 A EP 12859158A EP 2794007 A4 EP2794007 A4 EP 2794007A4
Authority
EP
European Patent Office
Prior art keywords
thrombosis
compositions
treatment
methods
prolonging survival
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12859158.3A
Other languages
German (de)
English (en)
Other versions
EP2794007A1 (fr
Inventor
Gray Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasculogics Inc
Original Assignee
Vasculogics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasculogics Inc filed Critical Vasculogics Inc
Publication of EP2794007A1 publication Critical patent/EP2794007A1/fr
Publication of EP2794007A4 publication Critical patent/EP2794007A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP12859158.3A 2011-12-23 2012-12-22 Compositions et procédés pour le traitement de thrombose et la prolongation de la survie de plaquettes stockées Withdrawn EP2794007A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161580110P 2011-12-23 2011-12-23
PCT/US2012/071530 WO2013096932A1 (fr) 2011-12-23 2012-12-22 Compositions et procédés pour le traitement de thrombose et la prolongation de la survie de plaquettes stockées

Publications (2)

Publication Number Publication Date
EP2794007A1 EP2794007A1 (fr) 2014-10-29
EP2794007A4 true EP2794007A4 (fr) 2015-11-18

Family

ID=48669595

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12859158.3A Withdrawn EP2794007A4 (fr) 2011-12-23 2012-12-22 Compositions et procédés pour le traitement de thrombose et la prolongation de la survie de plaquettes stockées

Country Status (3)

Country Link
EP (1) EP2794007A4 (fr)
CA (1) CA2871057A1 (fr)
WO (1) WO2013096932A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10081678B2 (en) 2013-02-04 2018-09-25 Emory University Specific binding antibodies of glycoprotein IB alpha as selective ectodomain shedding inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011162831A2 (fr) * 2010-06-24 2011-12-29 Vasculogics, Inc. Compositions et procédés pour le traitement de la thrombose et la prolongation de la survie de plaquettes stockées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035779A1 (es) * 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos
KR20060022261A (ko) * 2003-06-11 2006-03-09 와이어쓰 혈소판 당단백질 ｉｂ 알파 변이체 융합 폴리펩티드 및이의 사용 방법
PT2591006T (pt) * 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011162831A2 (fr) * 2010-06-24 2011-12-29 Vasculogics, Inc. Compositions et procédés pour le traitement de la thrombose et la prolongation de la survie de plaquettes stockées

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BENARD S A ET AL: "Identification of peptide antagonists to glycoprotein Ib[alpha] that selectively inhibit von Willebrand factor dependent platelet aggregation", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 47, no. 16, 22 April 2008 (2008-04-22), pages 4674 - 4682, XP002605297, ISSN: 0006-2960, [retrieved on 20080326], DOI: 10.1021/BI702428Q *
KAREN VANHOORELBEKE ET AL: "Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential", CURRENT PHARMACEUTICAL DESIGN, vol. 13, no. 26, 1 September 2007 (2007-09-01), pages 2684 - 2697, XP055091439, ISSN: 1381-6128, DOI: 10.2174/138161207781662867 *
MCEWAN P A ET AL: "Glycoprotein Ib[alpha] inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 114, no. 23, 26 November 2009 (2009-11-26), pages 4883 - 4885, XP002605298, ISSN: 0006-4971, [retrieved on 20090902], DOI: 10.1182/BLOOD-2009-05-224170 *
See also references of WO2013096932A1 *
VIKTORIA RUMJANTSEVA ET AL: "Dual roles for hepatic lectin receptors in the clearance of chilled platelets", NATURE MEDICINE, vol. 15, no. 11, 27 November 2009 (2009-11-27), pages 1273 - 1280, XP055065743, ISSN: 1078-8956, DOI: 10.1038/nm.2030 *

Also Published As

Publication number Publication date
WO2013096932A1 (fr) 2013-06-27
EP2794007A1 (fr) 2014-10-29
CA2871057A1 (fr) 2013-06-27

Similar Documents

Publication Publication Date Title
HK1218836A1 (zh) 協同細菌組合物和其製造方法和用途
HK1210957A1 (en) Effluz inhibitor compositions and methods of treatment using the same
EP2771030A4 (fr) Compositions et méthodes de traitement de protéinopathies
HK1258530A1 (zh) Serpina 1 sirnas:物質的組合物和治療方法
EP2603202A4 (fr) Compositions et méthodes pour traiter une tauopathie
PT2776567T (pt) Composições e métodos para o tratamento de citomegalovírus
EP2675471A4 (fr) Compositions liées à la sérumalbumine humaine et procédés d'utilisation
IL228984A0 (en) Preparations and methods for stabilization of active agents
EP2678018A4 (fr) Combinaison d'inhibiteurs des kinases et utilisations associées
SG11201400668SA (en) Wnt compositions and therapeutic uses of such compositions
EP2773212A4 (fr) Méthodes et compositions utilisées pour le traitement de l'autisme
EP2717855A4 (fr) Procédés de traitement
EP2688594A4 (fr) Procédés et compositions pour le traitement du cancer
ZA201408056B (en) Compositions and methods for the treatment of mucositis
EP2718277A4 (fr) Méthodes et compositions pour le traitement de la toxicité mitochondriale
PL3581199T3 (pl) Sposoby leczenia lub zmniejszania panikulopatii obrzękowo- zwłóknieniowo-stwardnieniowej
EP2663576A4 (fr) Nouvelles compositions de wnt et utilisations thérapeutiques de ces compositions
IL228205B (en) Compositions and methods for treatment of intracellular damage
IL227924B (en) Preparations and methods of use for determining a4he
EP2755668A4 (fr) Compositions dérivées de hyr1 et méthodes de traitement les utilisant
EP2867298A4 (fr) Compositions de polyacrylate biocompatible et leurs procédés d'utilisation
EP2670243A4 (fr) Compositions et procédés pour le traitement du glaucome
EP2585093A4 (fr) Compositions et procédés pour le traitement de la thrombose et la prolongation de la survie de plaquettes stockées
EP2935294A4 (fr) Méthodes et compositions pour le traitement de la toxicité du cyanure et de sulfure d'hydrogène
IL230988A0 (en) Combinations of corroles and statins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151019

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 7/02 20060101AFI20151013BHEP

Ipc: A61K 38/12 20060101ALI20151013BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160518